Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 7/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690899 | 0.83 | CYP2D6 (0.55) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5468494 | 0.81 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL607503 | 0.81 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1260631 | 0.81 | CYP2D6 (0.53) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL10947878 | 0.80 | CYP2D6 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL318355 | 0.79 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL5081830 | 0.79 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14016296 | 0.79 | CYP2D6 (0.51) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL530346 | 0.79 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21811455 | 0.79 | CYP2D6 (0.47) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-117693509-A | Macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| CN-107625953-A | For preventing and/or treating the medicine of polycystic kidney disease | 大塚制药株式会社 | 2018-01-26 | — | — | CN | disclosed |
| CN-104334176-B | Medicine for preventing and/or treating polycystic kidney disease | 大塚制药株式会社 | 2018-01-02 | — | — | CN | disclosed |
| EP-2854815-B1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMA CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| CN-1069728-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1993-03-10 | — | — | CN | disclosed |
| CN-1066653-A | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1992-12-02 | — | — | CN | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0450097-A1 | BENZOHETEROCYCLIC COMPOUNDS. | OTSUKA PHARMA CO LTD (JP) | 1991-10-09 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| CN-1051038-A | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1991-05-01 | — | — | CN | disclosed |
| CN-1046529-A | Carbostyril derivative | OTSUKA PHARMA CO LTD (JP) | 1990-10-31 | — | — | CN | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | CYP2D6 1716/4885HDAC3 619/4885HDAC1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.